LPTX - Leap Therapeutics Inc Stock Price, Fair Value and News

$2.53-0.05 (-1.94%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LPTX Price Action

Last 7 days

-7.7%

Last 30 days

-17.3%

Last 90 days

-7.0%

Trailing 12 Months

-11.5%

LPTX RSI Chart

LPTX Valuation

Market Cap

96.9M

Price/Earnings (Trailing)

-1.5

Price/Sales (Trailing)

104.41

EV/EBITDA

-0.64

Price/Free Cashflow

-1.76

LPTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-15.1%

Rev. Growth (Qtr)

2.85%

LPTX Earnings

Earnings (TTM)

-64.6M

Earnings Growth (Yr)

-32.71%

Earnings Growth (Qtr)

9.7%

LPTX Profitability

EBT Margin

-7394.55%

Return on Equity

-131.94%

Return on Assets

-99.3%

Free Cashflow Yield

-56.91%

LPTX Investor Care

Shares Dilution (1Y)

49.88%

Diluted EPS (TTM)

-1.23

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.3M	2.0M	1.9M	1.1M
2022	1.4M	1.6M	1.8M	2.1M
2021	1.8M	1.8M	2.9M	1.2M
2020	2.2M	2.5M	2.8M	1.8M
2019	1.0M	1.3M	1.6M	1.9M
2018	1.5M	1.2M	995.8K	756.0K
2017	2.8M	2.4M	2.1M	1.7M
2016	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

CEO	Mr. Douglas E. Onsi J.D.
WEBSITE	leaptx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	44

Leap Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Leap Therapeutics Inc? What does LPTX stand for in stocks?

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Leap Therapeutics Inc (LPTX)?

As of Fri Nov 22 2024, market cap of Leap Therapeutics Inc is 96.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers.

Is Leap Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LPTX is over valued or under valued. Whether Leap Therapeutics Inc is cheap or expensive depends on the assumptions which impact Leap Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPTX.

What is Leap Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, LPTX's PE ratio (Price to Earnings) is -1.5 and Price to Sales (PS) ratio is 104.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.